Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.48 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.46 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21944590 | 0.90 | KDM4A (0.45) | MRGPRX4SCN3ASCN9ASCN1ASCN2A | |
| SCHEMBL18002187 | 0.83 | SCN9A (0.46) | MRGPRX4SCN3ASCN9ASCN1ASCN2A | |
| SCHEMBL21945042 | 0.81 | MRGPRX4 (0.47) | MRGPRX4PPARAMAOB | |
| SCHEMBL21945535 | 0.78 | HRH3 (0.43) | MRGPRX4S1PR1MAOB | |
| SCHEMBL21944924 | 0.76 | MRGPRX4 (0.42) | MRGPRX4SCN9A | |
| SCHEMBL18004429 | 0.76 | SCN3A (0.39) | MRGPRX4SCN3ASCN9ASCN1ASCN2A | |
| SCHEMBL21944597 | 0.74 | FFAR1 (0.39) | MRGPRX4MAOB | |
| SCHEMBL21944603 | 0.74 | MAOB (0.53) | MAOB | |
| SCHEMBL21945045 | 0.74 | MAOB (0.54) | MRGPRX4MAOB | |
| SCHEMBL18002730 | 0.73 | MAOA (0.44) | MRGPRX4SCN3ASCN9ASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | MRGPRX4 4062/4885SCN3A 1758/4885SCN9A 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.